Termination Agreement between MedImmune, LLC and Cornerstone Therapeutics Inc. (June 1, 2010)

Contract Categories: Business Operations › Termination Agreements
Summary

MedImmune, LLC and Cornerstone Therapeutics Inc. have agreed to terminate their Exclusive License and Collaboration Agreement, originally effective July 30, 2003, along with any amendments and all related rights and obligations. As of June 1, 2010, neither party will have any further rights or responsibilities under the terminated agreement, regardless of when those obligations arose. This termination is final and overrides any previous terms to the contrary.

Read More Arrow
EX-10.2 3 b81582exv10w2.htm EX-10.2 exv10w2
Exhibit 10.2
TERMINATION AGREEMENT
     THIS TERMINATION AGREEMENT is effective as of June 1, 2010 (the “Effective Date”) between MEDIMMUNE, LLC., a limited liability corporation organized and existing under the laws of Delaware (“MEDIMMUNE”) and CORNERSTONE THERAPEUTICS INC., a corporation organized and existing under the laws of Delaware (“CTI”).
     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows:
     As of the Effective Date, CTI and MEDIMMUNE hereby terminate the Exclusive License and Collaboration Agreement effective as of July 30, 2003 by and between MEDIMMUNE and CTI, and any amendments made thereto, and the rights and licenses granted thereunder and any and all rights and obligations thereunder, including those incurred prior to, as of or subsequent to the Effective Date, and no rights or obligations of the Exclusive License and Collaboration Agreement will survive such termination, including but not limited to the obligations of Section 10.4 of the Exclusive License and Collaboration Agreement notwithstanding anything in the Exclusive License and Collaboration Agreement to the contrary
     IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date(s) set forth below.
           
MEDIMMUNE, LLC.    Cornerstone Therapeutics Inc. 
 
BY:  /s/ Sun Park    BY:  /s/ Andrew Powell   
 
TITLE: VP, Business Development
     TITLE: Secretary
 
DATE: 6/21/10
 		   DATE: 6/29/10